Tyber Medical was awarded a $225,000 Small Business Innovation Research grant from the National Science Foundation to conduct research and development relating to reducing orthopedic surgical site infections.
Tyber Medical has developed the BioTy™ nanotextured implant surface. This work builds upon fundamental research into the control of bacterial growth on implant surfaces using topography alone, without antimicrobial agents or pharmaceuticals to which bacteria could form resistance. In 2016, the company received its first FDA 510(k) clearance of BioTy for use on its Headless Screw System.
Of note, once a small business is awarded a Phase I SBIR grant (up to $225,000), it is eligible to apply for a Phase II grant (up to $750,000). Small businesses with Phase II grants are eligible to receive up to $500,000 in additional matching funds with third-party investment or sales.
Tyber Medical was awarded a $225,000 Small Business Innovation Research grant from the National Science Foundation to conduct research and development relating to reducing orthopedic surgical site infections.
Tyber Medical has developed the BioTy™ nanotextured implant surface. This work builds upon fundamental research into the control of...
Tyber Medical was awarded a $225,000 Small Business Innovation Research grant from the National Science Foundation to conduct research and development relating to reducing orthopedic surgical site infections.
Tyber Medical has developed the BioTy™ nanotextured implant surface. This work builds upon fundamental research into the control of bacterial growth on implant surfaces using topography alone, without antimicrobial agents or pharmaceuticals to which bacteria could form resistance. In 2016, the company received its first FDA 510(k) clearance of BioTy for use on its Headless Screw System.
Of note, once a small business is awarded a Phase I SBIR grant (up to $225,000), it is eligible to apply for a Phase II grant (up to $750,000). Small businesses with Phase II grants are eligible to receive up to $500,000 in additional matching funds with third-party investment or sales.
Copy to clipboard 
